Quick Takeaways
- James E. Flynn filed SCHEDULE 13G/A for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX).
- Disclosed ownership: 2.6%.
- Date of event: 31 Dec 2024.
James E. Flynn - 31 Dec 2024 SCHEDULE 13G/A Report for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX)
- Filing Manager
- James E. Flynn
- Reporting Manager
- Deerfield Mgmt, L.P.
- Symbol
- CPRX
- Shares outstanding
- 119,125,894 shares
- Disclosed Ownership
- 3,133,011 shares
- Ownership
- 2.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2025, 08:57:09 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"James E. Flynn disclosed 2.6% ownership in Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Feb 2025, 08:57.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deerfield Mgmt, L.P. | 2.6% | 3,133,011 | 0 | 3,133,011 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| Deerfield Management Company, L.P. | 2.6% | 3,133,011 | 0 | 3,133,011 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| Deerfield Partners, L.P. | 2.6% | 3,133,011 | 0 | 3,133,011 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| James E. Flynn | 2.6% | 3,133,011 | 0 | 3,133,011 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact |